Hepatoblastoma
What is Hepatoblastoma?
Hepatoblastoma is a rare type of liver cancer that occurs mainly in children. It typically affects infants and children under 5 years old. This cancer starts in the cells of the liver and can grow quickly.
The liver is a vital organ that filters blood and helps digest food. When hepatoblastoma develops, abnormal cells multiply and form a tumor. This tumor can interfere with how the liver works. Most cases are diagnosed before age 3, making it primarily an early childhood condition.
Hepatoblastoma accounts for about 1% of all childhood cancers. It is the most common type of liver cancer in young children. Early detection and treatment can lead to positive outcomes. Many children who receive proper care can recover fully.
Symptoms
- Swollen or enlarged belly that may look lopsided
- A hard mass or lump felt in the abdomen
- Pain or discomfort in the belly area
- Loss of appetite and weight loss
- Nausea and vomiting
- Yellowing of the skin and eyes, called jaundice
- Fever without obvious infection
- Fatigue and irritability
- Pale skin due to anemia
Some children may have few symptoms in the early stages. The most common first sign is a swollen belly or a mass that parents can feel during bath time or diaper changes.
Concerned about Hepatoblastoma? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
The exact cause of hepatoblastoma remains unclear in most cases. Certain genetic conditions can increase risk, including Beckwith-Wiedemann syndrome and familial adenomatous polyposis. Premature birth and very low birth weight are also risk factors. Some children with hepatoblastoma have a family history of specific genetic changes.
Researchers have found links to increased levels of IGF-2, a protein that promotes cell growth. When IGF-2 levels are too high, cells may grow and divide uncontrollably. This can lead to tumor formation. Most cases occur randomly without a clear family history or known cause.
How it's diagnosed
Doctors diagnose hepatoblastoma through several methods. Physical examination may reveal an enlarged liver or abdominal mass. Imaging tests like ultrasound, CT scans, and MRI help doctors see the tumor clearly. Blood tests can measure certain markers, including alpha-fetoprotein, which is often very high in hepatoblastoma cases.
Specialized testing for biomarkers like IGF-2 may provide additional information about the tumor. A biopsy, where a small tissue sample is removed and examined, confirms the diagnosis. Talk to your doctor about specialized testing options. These advanced tests help determine the best treatment approach for your child.
Treatment options
- Surgery to remove the tumor is the primary treatment when possible
- Chemotherapy to shrink tumors before surgery or kill remaining cancer cells
- Liver transplant in cases where the tumor cannot be fully removed
- Nutritional support to help children maintain strength during treatment
- Regular monitoring with blood tests and imaging after treatment
- Pain management and supportive care throughout the treatment process
- Long-term follow-up care to watch for any signs of recurrence
Frequently asked questions
Hepatoblastoma primarily affects children under 5 years old. Most cases are diagnosed in infants and toddlers before age 3. It is extremely rare in older children and adults. Early childhood is the most vulnerable period for this type of liver cancer.
Hepatoblastoma is very rare, accounting for about 1% of all childhood cancers. Only about 100 to 150 cases are diagnosed each year in the United States. Despite being rare overall, it is the most common type of liver cancer in young children. The rarity means specialized pediatric oncology care is essential.
Survival rates have improved significantly with modern treatment. When caught early and treated properly, the 5-year survival rate can exceed 70%. Factors affecting outcomes include tumor size, stage at diagnosis, and how well it responds to chemotherapy. Early detection and treatment at specialized centers provide the best chances for recovery.
There is no known way to prevent hepatoblastoma in most cases. The condition typically occurs randomly without clear preventable causes. Regular pediatric checkups can help catch any abnormalities early. Parents of children with known genetic risk factors should discuss monitoring options with their doctor.
IGF-2 is a protein that helps cells grow and divide. In hepatoblastoma, IGF-2 levels are often abnormally high. This excess IGF-2 can cause liver cells to grow out of control, forming tumors. Measuring IGF-2 levels may help doctors understand the tumor and plan treatment.
The most common first sign is a swollen or enlarged belly. Parents may notice one side of the abdomen looks larger than the other. A hard mass or lump may be felt during bath time or diaper changes. Any unusual swelling or lumps in a child's abdomen should be evaluated by a doctor immediately.
Hepatoblastoma specifically affects the liver, while most childhood cancers affect blood or lymph tissue. It occurs almost exclusively in very young children, usually before age 5. The treatment approach often involves both surgery and chemotherapy. It responds well to treatment when caught early, offering good recovery prospects.
Pediatric oncologists, doctors who specialize in childhood cancers, lead the treatment team. Pediatric surgeons perform operations to remove tumors. Other specialists may include radiologists, pathologists, and transplant surgeons if needed. Treatment typically occurs at specialized children's hospitals with experience in rare cancers.
Most children with hepatoblastoma receive chemotherapy as part of their treatment plan. Chemotherapy may be given before surgery to shrink the tumor. It is also used after surgery to kill any remaining cancer cells. The specific treatment plan depends on the tumor's size, stage, and characteristics.
Treatment duration varies based on the tumor's stage and response to therapy. Most children undergo several months of chemotherapy combined with surgery. The entire treatment process often takes 6 to 12 months. After treatment ends, regular follow-up visits continue for years to monitor for any recurrence.